CClinicalTrials.gg
Status unknownNCT05631015Updated Nov 30, 2022

Artificial Intelligence for Determination of Gastroscopy Surveillance Intervals

An observational study in Helicobacter Pylori Infection, Atrophic Gastritis and Intestinal Metaplasia, sponsored by Xiuli Zuo. Status unknown at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-11-30.

Sponsored by Xiuli Zuo · Observational

The sponsor has not verified this record recently (last verified Nov 2022), so the status shown — last known as Active, not recruiting — may be out of date.
Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
2,000
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is to develop and validate a clinical decision support system based on automated algorithms. This system can use natural language processing to extract data from patients' endoscopic reports and pathological reports, identify patients' disease types and grades, and generate guidelines based follow-up or treatment recommendations

02

Conditions studied

  • Helicobacter Pylori Infection
  • Atrophic Gastritis
  • Intestinal Metaplasia
  • Low Grade Intraepithelial Neoplasia
  • High Grade Intraepithelial Neoplasia
  • Early Gastric Cancer
  • Gastric Cancer
03

In context

Stomach Neoplasms

2,851 studies on the registry are indexed under Stomach Neoplasms; 864 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 274 across 670 observational studies indexed under Stomach Neoplasms.

Browse Stomach Neoplasms studies →

Lead sponsor

Xiuli Zuo is the lead sponsor of 10 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

patients who came to Qilu Hospital of Shandong University and received endoscopy examination but not therapeutic endoscopy

Inclusion criteria

  • Patients aged 18 - 80 years
  • Patients underwent endoscopic examination

Exclusion criteria

Exclusion Criteria:

  • Patients with the contraindications to endoscopic examination
  • Patients with imcomplete examination information
  • Patients undergo endoscopy for therapy
  • Patients have history of upper gastrointestinal surgery
  • Patients with duodenal or Laryngeal neoplasms
  • Patients with gastrointestinal submucosal tumor
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
2,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Artificial Intelligence support decision group

    According the endoscopic reports and pathological reports, the decision support system recognise patients' disease types and grades, and generate guidelines based survilliance or treatment recommendations.

    Other: AI recongnize disease and generate recommendations

Interventions

  • OtherAI recongnize disease and generate recommendations

    According the endoscopic reports and pathological reports, the decision support system recognise patients' disease types and grades, and generate guidelines based survilliance or treatment recommendations.

06

What researchers measure

Primary outcomes

  1. The diagnostic accuracy of gastric diseases with deep learning algorithm

    The diagnostic accuracy of gastric diseases with deep learning algorithm

    Time frame: 12 month

  2. The accuracy of recommentions for different disease with deep learning algorithm

    The accuracy of recommentions for different disease with deep learning algorithm

    Time frame: 12 month

Secondary outcomes

  1. The diagnostic sensitivity of gastric diseases with deep learning algorithm

    The diagnostic sensitivity of gastric diseases with deep learning algorithm

    Time frame: 12 month

  2. The diagnostic specificity of gastric diseases with deep learning algorithm

    The diagnostic specificity of gastric diseases with deep learning algorithm

    Time frame: 12 month

  3. The diagnostic positive predictive value of gastric diseases with deep learning algorithm

    The diagnostic positive predictive valu of gastric diseases with deep learning algorithm

    Time frame: 12 month

  4. The diagnostic negative predictive value of gastric diseases with deep learning algorithm

    The diagnostic negative predictive value of gastric diseases with deep learning algorithm

    Time frame: 12 month

  5. The F-score of gastric diseases with deep learning algorithm

    The F-score of gastric diseases with deep learning algorithm

    Time frame: 12 month

07

Study locations

1 site
  • Qilu Hospital, Shandong University
    Jinan, Shandong 250012, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 30, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05631015
Lead sponsor
Xiuli Zuo
Responsible party
Xiuli Zuo (director of Qilu Hospital gastroenterology department, Shandong University) — Sponsor-investigator
First posted
Nov 30, 2022
Start date
Jan 1, 2012
Primary completion
Oct 31, 2022
Completion
Dec 31, 2023 (estimated)
Last update
Nov 30, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion